Targeting NF-κB Signaling for Multiple Myeloma.

ABSTRACT: Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM therapies, focusing on anti-MM drugs that target the molecular mechanisms of nuclear factor kappa B (NF-κB) signaling. We also provide our perspectives on contemporary research findings and insights for future drug development.

SUBMITTER: Wong AH 

PROVIDER: S-EPMC7463546 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature